title: Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels.
abstract: BACKGROUND
  The German Lipoprotein Apheresis Registry (DLAR) has been initiated by members of the Nephrology Foundation (WiNe), the German association of kidney centres (DN), the German society of nephrology (DGfN) and additional medical associations taking part in the apheresis working group. Its goal is the introduction of a substantial database, suitable to provide statistical evidence for the assessment of extracorporeal procedures. Data have been added to the DLAR since October 2011. In this article, preliminary results are first reported.
  
  
  RESULTS
  Data are stored on a secured Internet platform. The recorded information comprises mean values and rates of change in lipid levels (cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, lipoprotein(a) (Lp(a)) before and after apheresis therapy, blood/plasma volume, frequency and type of adverse effects, medication, vascular events, diagnoses and comorbidity. It is collected by participating apheresis centres from all over Germany. Up until October 2014, a total of 7946 lipoprotein apheresis (LA) treatments of 991 patients (787 with documented LDL-C and 688 with documented Lp(a) levels) via 96 medical accounts were documented and analysed. The current share of Lp(a) patients is 50.6 % (Lp(a) ≥ 60 mg/dl; n = 348/688). For both LDL-C and Lp(a), lowering rates exceeding 60 % have been observed. Likely in conjunction with these reduction rates, the preliminary analysis shows a 90 % decline in major adverse coronary events (MACE) as well as a decrease in major adverse non-coronary events (MANCE) by 69 %. As before, good tolerability and low rates of adverse effects (< 3 %) of LA therapy were found.
  
  
  CONCLUSIONS
  The available numbers suggest in parts very good response by the participating centres to the DLAR. Unfortunately, there are also centres that have not documented any patients so far or LA treatments at all. The benchmark values for reduction rates in lipoprotein concentration required by the directives of the German Federal Joint Committee (G-BA) have all been met. The decrease in MACE and MANCE rates currently observed is very promising. However, the comparably short runtime of the registry does not allow for high confidence in the current results. Certainly, reliable data will be extractable in the coming years. Given the high interest expressed by European neighbours, the extension of the registry to the European level should be a future goal for the DLAR as well.
authors: Centre of Nephrology Göttingen GbR, An der Lutter 24, 37075, Göttingen, Germany, v.schettler@nz-goe.de.
authors: Volker J J
authors: VJ
authors: Schettler
authors: Class L
authors: CL
authors: Neumann
authors: Christian
authors: C
authors: Peter
authors: Thomas
authors: T
authors: Zimmermann
authors: Ulrich
authors: U
authors: Julius
authors: Eberhard
authors: E
authors: Roeseler
authors: Franz
authors: F
authors: Heigl
mesh_terms: D001781:Blood Component Removal / Q000706:statistics & numerical data*; D005858:Germany / Q000453:epidemiology; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000453:epidemiology* / Q000517:prevention & control*; D015994:Incidence; D017270:Lipoprotein(a) / Q000097:blood* / Q000302:isolation & purification*; D015995:Prevalence; D012042:Registries / Q000706:statistics & numerical data*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D017270:Lipoprotein(a)
references: Atheroscler Suppl. 2013 Jan;14(1):89-92
references: 23357148
references: Atheroscler Suppl. 2013 Jan;14(1):51-5
references: 23357141
references: Circulation. 2013 Dec 17;128(24):2567-76
references: 24056686
references: Atheroscler Suppl. 2013 Jan;14(1):29-32
references: 23357137
references: Atheroscler Suppl. 2013 Jan;14(1):19-27
references: 23357136
references: Clin Res Cardiol Suppl. 2012 Jun;7:7-14
references: 22911176
references: Clin Res Cardiol Suppl. 2012 Jun;7:15-9
references: 22528134
references: Eur Heart J. 2010 Dec;31(23):2844-53
references: 20965889
references: Nat Clin Pract Cardiovasc Med. 2009 Mar;6(3):229-39
references: 19234501
references: Eur J Public Health. 2006 Apr;16(2):217-22
references: 16093306
references: Nat Rev Cardiol. 2014 Oct;11(10):563-75
references: 24958078
references: Eur Heart J. 2014 Sep 1;35(33):2249-59
references: 24598985